These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28652707)

  • 1. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
    Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
    Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
    Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C
    Ajani JA; Javle M; Eng C; Fogelman D; Smith J; Anderson B; Zhang C; Iizuka K
    Invest New Drugs; 2020 Dec; 38(6):1763-1773. PubMed ID: 32377978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
    Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.
    Ochiai T; Umeki M; Miyake H; Iida T; Okumura M; Ohno K; Sakamoto M; Miyoshi N; Takahashi M; Tsumura H; Tokunaga Y; Naitou H; Fukui T
    Oncol Rep; 2014 Sep; 32(3):887-92. PubMed ID: 24994673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
    Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
    Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery of oral anti-cancer fluoropyrimidine agents.
    Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
    Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
    Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
    Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
    Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
    Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T
    BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].
    Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Yamashita K; Tajiri T
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1603-9. PubMed ID: 17108726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
    Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
    Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
    Biol Pharm Bull; 2013; 36(6):907-16. PubMed ID: 23575271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.